美国 · 交易所与实时行情 · Nasdaq

Gilead To Buy PepStar's IBD Investigational Oral IL-23R Inhibitor Program For $1.275 Bln Cash

来源：Nasdaq · 美国 2 小时前

(RTTNews) - Gilead Sciences, Inc. (GILD), a biopharmaceutical company, announced that it has reached an agreement to acquire investigational oral IL-23R inhibitor program,…

在 Nasdaq 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.nasdaq.com)

Gilead To Buy PepStar's IBD Investigational Oral IL-23R Inhibitor Program For $1.275 Bln Cash

推荐阅读

Eni's Profits Soar 125% as Refining Boom Fuels Massive Investor Payouts

Injective (INJ) Drops 8.9% Amid Broad Crypto Selloff

Gen Z Is Starting Businesses at a Record Pace. Here’s How

Tech Sell-Off Leads to Uptick in Defensive Stocks

Introducing new self-learning context enrichment in Knowledge Catalog

Gilead To Buy PepStar's IBD Investigational Oral IL-23R Inhibitor Program For $1.275 Bln Cash

分享

推荐阅读

Eni's Profits Soar 125% as Refining Boom Fuels Massive Investor Payouts

Injective (INJ) Drops 8.9% Amid Broad Crypto Selloff

Gen Z Is Starting Businesses at a Record Pace. Here’s How

Tech Sell-Off Leads to Uptick in Defensive Stocks

Introducing new self-learning context enrichment in Knowledge Catalog